NCT00760617 - Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older | Biotech Hunter

Enrollment

526

Participants

Timeline

Start Date

October 6, 2008

Primary Completion Date

May 15, 2009

Study Completion Date

May 15, 2009

Conditions

Influenza

Interventions

BIOLOGICAL

GSK Bio's influenza vaccine GSK2186877A

Intramuscular (IM) administration, 1 dose

BIOLOGICAL

Fluarix

Intramuscular (IM) administration, 1 dose

Trial Locations (25)

10435

GSK Investigational Site, Berlin

12627

GSK Investigational Site, Berlin

13347

GSK Investigational Site, Berlin

13359

GSK Investigational Site, Berlin

22335

GSK Investigational Site, Hamburg

22415

GSK Investigational Site, Hamburg

39112

GSK Investigational Site, Magdeburg

39326

GSK Investigational Site, Wolmirstedt

45359

GSK Investigational Site, Essen

51069

GSK Investigational Site, Cologne

55131

GSK Investigational Site, Mainz

55624

GSK Investigational Site, Rhaunen

68161

GSK Investigational Site, Mannheim

69469

GSK Investigational Site, Weinheim

73635

GSK Investigational Site, Rudersberg

74363

GSK Investigational Site, Güglingen

86150

GSK Investigational Site, Augsburg

01067

GSK Investigational Site, Dresden

01705

GSK Investigational Site, Freital

04103

GSK Investigational Site, Leipzig

3001 DC

GSK Investigational Site, Rotterdam

3011 EN

GSK Investigational Site, Rotterdam

SE-631 88

GSK Investigational Site, Eskilstuna

SE-371 41

GSK Investigational Site, Karlskrona

SE-751 85

GSK Investigational Site, Uppsala